Training Seminars

Cambridge Healthtech Institute Training Seminars offer real-life case studies, problems encountered and solutions applied, along with extensive coverage of the academic theory and background. Each Training Seminar offers a mix of formal lecture and interactive discussions and activities to maximize the learning experience. These Training Seminars are led by experienced instructors who will focus on content applicable to your current research and provide important guidance for those new to their fields.

TS9A: Introduction to Structure-Based Drug Design and Development



8:30 am - 12:30 pm Seminar Sessions
2:20 - 1:30 Problem Solving Breakout Discussions
4:00 - 5:40 Plenary Keynote Session
5:40 - 7:15 pm Welcome Reception in the Exhibit Hall with Poster Viewing


8:30 am - 5:25 pm Seminar Sessions
12:30 - 1:00 pm Lunch Provided

Exhibit Hall Refreshment Breaks also provided.



Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada

Traian Sulea, PhD, Principal Research Officer, Human Health Therapeutics, National Research Council Canada


CHI’s Introduction to Structure-based Biologics Design and Development offers an introduction to the concepts, strategies and tools of structure-based biologics design, optimization and development. The seminar consists of presentations and live demonstrations of some of the common computational tools used in the field. We will cover techniques to triage therapeutics sequences, modulate affinity, create novel constructs (such as Fc-fusions, bispecifics, protein traps) along with increasing the manufacturability of a biologic. The class is directed at scientists new to the industry, academic scientists and career protein engineers wanting an introduction into how structure can aid in guiding experimental design.

Topics to Be Discussed:

  • Basics of structural modeling and where does it fit into drug discovey
  • Affinity and specificity engineering of biologics
  • Engineering bispecific antibodies, fusion proteins and ADCs
  • Designing novel pharmacokinetics and immune effector function profiles
  • Structure-based developability assessment (folding, chemical and proteolytic stability)
  • Structural aspects of protein aggregation and immunogenicity prediction
  • Humanization by design
  • Engineering pH specificity using molecular modeling; structural aspects of CAR optimization

Instructor Biographies:

Corbeil_ChristopherChristopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada

Dr. Christopher Corbeil is a Research Officer at the National Research Council Canada (NRC) who specializes in the development and application of computational tools for biotherapeutic design and optimization. He also teaches classes in Structure-Based Drug Design at McGill University. After receiving his Ph.D. from McGill University, he joined the NRC as a Research Associate investigating the basics of protein-binding affinity. Following his time at the NRC he joined Chemical Computing Group as a Research Scientist developing tools for protein design, structure prediction and binding affinity prediction. He then decided to leave private industry and rejoin NRC with a focus on antibody engineering. Dr. Corbeil has authored 25 scientific articles and is the main developer of multiple software programs.

Sulea_TraianTraian Sulea, PhD, Principal Research Officer, Human Health Therapeutics, National Research Council Canada

Dr. Traian Sulea is a Principal Research Officer who joined the National Research Council Canada as a post-doctoral fellow in 1995. He is also Adjunct Professor at the Institute of Parasitology of McGill University since 2012. Dr. Sulea has broad expertise in applying computational approaches to the discovery and optimization of bioactive small-molecules and biologics. He has contributed to the development of computational methods for biomolecular applications, focusing on continuum solvation models and binding-affinity scoring functions. He has applied structural modeling for bioengineering of growth-factor traps and selective tumor targeting, as well as antibody humanization, conjugation, affinity maturation, de novo design, and developability. Dr. Sulea has authored 95 scientific articles and book chapters and is an inventor on 29 patents issued or pending.


Each CHI Training Seminar offers 1.5 days of instruction, refreshment breaks, exhibit hall functions, and lunch for all registered attendees on the full day of the class. Each person registered for the Training Seminar will be provided with a hard copy handbook for the Training Seminar in which they are registered. A limited number of additional handbooks may be available for other delegates. CHI encourages track hopping between conference programs, and we ask that Training Seminars not be disturbed once they have begun. We ask that attendees commit to attending the entire 1.5-day training, and not engage in track hopping once the class has started.